Moderna's narrative is shifting as analysts modestly trim their fair value from $37.32 to $35.78 per share and nudge the ...

Super Micro's headwinds stemming from AI-bubble fears contrast with improving compliance, new Nvidia-powered products, and a ...

Moderna Inc. (NASDAQ: MRNA) is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 ...

The Dow Jones index fell on the stock market today. Synopsys popped on an investment from AI giant Nvidia. A gold stock cleared an entry.

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft sales ...

Moderna (MRNA) slipped about 6% after an FDA official said future vaccine approvals will face tougher scrutiny, a shift tied ...

Moderna (NASDAQ:MRNA – Get Free Report) had its price objective lowered by analysts at JPMorgan Chase & Co. from $40.00 to $33.00 in a research note issued on Friday,Benzinga reports. The firm ...

Moderna (NASDAQ:MRNA – Free Report) had its target price trimmed by Barclays from $45.00 to $40.00 in a research note released on Friday morning,Benzinga reports. The firm currently has an equal ...

Moderna, Inc. (NASDAQ:MRNA) shares are trading higher Friday after the company received Health Canada approval for the updated COVID-19 vaccine. What To Know: Health Canada authorized Moderna's ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $22.0 to $39.0 for Moderna over the last 3 months.

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Moderna shares may remain under the microscope on Tuesday after sinking to a five-year low ...